Treatment with ST707 reduced these pro-inflammatory cytokines by 40.2% (TNF-α) and 36.7% (IL-1β), while AD808 demonstrated superior efficacy, with reductions of 57.3% (TNF-α) and 61.5% (IL-1β) relative to AD controls. This evidence concerns the gene IL1B and Alzheimer disease.